Intelligence · Clinical Pipeline
CORCEPT THERAPEUTICS Pipeline
All ClinicalTrials.gov programs at CORCEPT THERAPEUTICS — phase, modality, and trial IDs.
- Programs
- 11
Quick answer
CORCEPT THERAPEUTICS has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
CORCEPT THERAPEUTICS INC
Endogenous Cushing Syndrome
1 trial -
Mifepristone
CORCEPT THERAPEUTICS INC
Depressive Disorder, Major
1 trial -
Nab-paclitaxel 80 mg/m^2
CORCEPT THERAPEUTICS INC
Ovarian Neoplasm
1 trial -
Relacorilant
CORCEPT THERAPEUTICS INC
Hypercortisolism
1 trial -
Relacorilant, 100 mg and 25 mg
CORCEPT THERAPEUTICS INC
Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
mifepristone
CORCEPT THERAPEUTICS INC
Major Depressive Disorder
5 trials -
mifepristone
CORCEPT THERAPEUTICS INC
Psychotic Depression
1 trial -
mifepristone
CORCEPT THERAPEUTICS INC
Cushing's Syndrome
2 trials -
mifepristone
CORCEPT THERAPEUTICS INC
Cushing's Disease
2 trials -
relacorilant
CORCEPT THERAPEUTICS INC
Cushing Syndrome
2 trials -
relacorilant, CORT125134, Abraxane 5 mg/ml powder for dispersion for infusion.
CORCEPT THERAPEUTICS INC
Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
1 trial
Frequently asked questions
How many pipeline programs does CORCEPT THERAPEUTICS have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs